



Press release | ECULLY, FRANCE - April 14, 2020

Seqens plans to invest in a new production plant for isopropanol

Seqens is a major European player in high value oxygenated solvents through its Solvents & Phenol Specialties Business Unit. It plans to invest in a second production plant for isopropanol (IPA) on the Roussillon chemical platform, France

With this expansion, Seqens' global annual production capacity of IPA will increase by more than 70%. The new unit, with a capacity of 50.000 metric tons per year, is planned to start up in 2021 and will benefit from an optimized production process based on the experience gained on Seqens' first production unit as well as competitive access to raw materials and energy to be supplied by the platform.

Thanks to this investment, Seqens will continue its downstream integration and will be able to meet further growing demand of IPA, including new high-end applications. This additional capacity will also allow the ramp up of the production of several downstream specialty products such as isopropyl acetate (IPAC) and diisopropyl ether (DIPE).

Isopropanol (IPA) is a solvent used in many industrial and consumer products. Seqens offers the highest quality products available on the market (Pharmaceutical, Cosmetic, Electronic and Technical grades) to serve the most demanding sectors, including pharmaceuticals, cosmetics, personal care, electronics and detergence.

Isopropyl acetate (IPAC) is used as a process solvent and in the extraction of organic products. Key applications include production of active pharmaceutical ingredients, inks for food packaging and production of cosmetics actives.

Diisopropyl ether (DIPE) is a high value solvent used as an extraction solvent in the pharmaceutical industry for manufacturing specific active ingredients. DIPE also plays a key role in the manufacturing process of numerous high value products such as coatings, resins, intermediates and high purity phosphoric acid.

About Seqens

Seqens is an integrated global leader in pharmaceutical synthesis and specialty ingredients.

With 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia, SEQENS develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare. Driven by a culture of excellence and a strong entrepreneurial spirit, SEQENS' 3,200 employees are committed to providing its customers with the highest level of service and product quality while acting ethically in alignment with our Corporate Social Responsibility program.

For more information please see www.seqens.com

Contact Seqens: press@seqens.com

www.seqens.com

SEQENS SAS, – 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex – Capital Social 226 890 746.63 euros – 444 465 736 00049 RCS Lyon – Tel : +33 (0)4 26 99 18 00 – Fax : +33 (0)4 26 99 18 38